INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 412m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN11m ago
SEC FORM 4/Open-market saleVerified data

Nagendran Sukumar sold TSHA

Director, President and Head of R&D · Taysha Gene Therapies, Inc. · Common Stock

Side
SELL
Value
$423K
Shares
89.1K
Price
$4.75
Executed
Jan 23, 2026
Disclosed
Jan 27, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 23 executedJan 27, 2026 disclosed

TSHA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
32/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+11 / 25

    $423K reported value · 6.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TSHA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M$33K
    19.0K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    11
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$892K
    200.0K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    0
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M—
    19.0K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    36
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$375K
    79.0K sh
    		Jan 23, 2026Jan 27, 2026
    traded Jan 23, 2026
    		+4dSEC FORM 4

    Evidence

    25
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$110K
    23.8K sh
    		Jan 26, 2026Jan 27, 2026
    traded Jan 26, 2026
    		+1dSEC FORM 4

    Evidence

    25
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$124K
    26.9K sh
    		Jan 26, 2026Jan 27, 2026
    traded Jan 26, 2026
    		+1dSEC FORM 4

    Evidence

    11
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M—
    111.3K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    7
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M—
    88.7K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    359.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    NP
    Nolan Sean P.Director, Chief Executive Officer
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    1.01M sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    NP
    Nolan Sean P.Director, Chief Executive Officer
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    648.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    0
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Grant or award · 10b5-1 plan
    		A—
    274.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    231.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    6
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M$78K
    111.3K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    6
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M$152K
    88.7K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$942K
    200.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    7
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Grant or award · 10b5-1 plan
    		A—
    427.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001665124-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 23, 2026
    Published
    Jan 27, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Nagendran Sukumar
    Role
    Director, President and Head of R&D
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Taysha Gene Therapies, Inc.
    Ticker
    TSHA
    Shares
    89.1K
    Price per share
    $4.75
    Value
    $423,377
    Execution date (reported)
    Jan 23, 2026
    Owned after transaction
    1.34M shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 89.1K
    • Price: $4.75

    = $423,377

    What this establishes

    Nagendran Sukumar filed this Form 4 reporting a open-market sale of TSHA on Jan 23, 2026. It became public on Jan 27, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and Head of R&D
    Nagendran Sukumarcik:0001665124
    Issuer
    Taysha Gene Therapies, Inc.cik:0001806310

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.